持续加强CDMO团队能力。为满足CDMO业务快速发展，CDMO人员同比增长29%，至492人，占集团总人数86%。ADCCDMO团队同比增幅27%，强化业务重心。Dongyang Pharmacy-B (01875.HK) announced that in the first half of 2024, the group's revenue was RMB 0.52 billion, a year-on-year increase of 59%. Among them, product sales revenue was RMB 0.4 billion, a year-on-year increase of 44%, mainly from the core product Bevacizumab Injection Pertuzumab Sales continued to climb. CDMO/CMO business income reached RMB 0.114 billion, a year-on-year increase of 144%. The hematopoietic capacity is robust, and the net cash flow from operating activities in the first half of the year was RMB 27,801,000, maintaining a positive trend. The strategic transformation of CDMO has achieved remarkable results, and sales of self-developed products have also steadily increased. Achieving a turnaround, net income in the first half of the year reached RMB 31,559,000.
The market position of biopharmaceutical CDMO continues to improve, with 20 new projects added in the first half of the year, totaling 115, of which 17 are ADCs; 2 new pre-BLA (pre-clinical declaration before listing) projects were added, totaling 8 in hand, locking in future commercial production; contracted unfinished orders have reached RMB 0.184 billion, a year-on-year increase of 104%; domestic and foreign customer visits continue to increase, and brand influence continues to expand.
The company has a quality management system that complies with GMP standards in China, the United States, and Europe, and has been widely recognized by the industry at home and abroad. As of June 30, 2024, it has accepted more than 60 GMP audits, including zero defects passed the EU QP audit, direct onsite approval from the Colombian official GMP audit, and passed GMP audits in countries such as Indonesia and Egypt. In addition, the company has cooperated with customers many times to complete inspections by overseas cooperative partners and institutional inspections of multinational pharmaceutical companies, and successfully cooperated with customers to obtain high recognition and authorization.
Continuously strengthening the CDMO team's capabilities. To meet the rapid development of CDMO business, the number of CDMO personnel increased by 29% year-on-year to 492, accounting for 86% of the group's total staff. The ADCCDMO team increased by 27% year-on-year to strengthen the business focus.
